Business · 28/09/2017Updated: 10/17/2026 · 1 min read
FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2018
Summary
The US Food and Drug Administration (FDA) has set the fee for using a rare pediatric disease priority review voucher for fiscal year 2018, based on the average costs incurred in reviewing human drug applications in the previous year.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →